MANE net incomeQ2 2026-$23.50M
MANE net income was -$23.50M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$15.64M a year earlier. For the full fiscal 2025 it was -$70.00M, compared with -$26.49M in fiscal 2024.
Veradermics Incorporated (MANE) financials
For fiscal 2025 (ended Dec 31, 2025), Veradermics Incorporated reported -$70.00M of net income.
- Net income, FY2025
- -$70.00M
- Free cash flow, FY2025
- -$71.63M
- EPS, diluted, FY2025
- -$111.91
- Cash
- $319.33M
- Market cap
- $6.01B
FY2024FY2025
FY2024FY2025
MANE revenue and earnings growth
MANE EPSQ2 2026-$0.58
MANE diluted EPS was -$0.58 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$111.91, compared with -$37.05 in fiscal 2024.
MANE free cash flowQ2 2026-$14.51M
MANE free cash flow was -$14.51M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$15.64M a year earlier. For the full fiscal 2025 it was -$71.63M, compared with -$23.69M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | $62.06M | $23.28M |
| Selling, general and admin | $10.28M | $3.50M |
| Operating income | -$72.35M | -$26.78M |
| Interest expense | $0 | $585.0K |
| Pre-tax income | -$70.00M | -$26.49M |
| Income tax | $0 | $0 |
| Net income | -$70.00M | -$26.49M |
| EPS, basic | -$111.91 | -$37.05 |
| EPS, diluted | -$111.91 | -$37.05 |
| Diluted shares | 744,991 | 736,933 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $21.77M | $53.08M |
| Current assets | $152.49M | $55.53M |
| Total assets | $152.62M | $55.53M |
| Current liabilities | $9.15M | $4.72M |
| Total liabilities | $9.16M | $4.72M |
| Shareholders' equity | -$121.01M | -$48.48M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$71.60M | -$23.69M |
| Capital expenditures | $24.0K | $0 |
| Free cash flow | -$71.63M | -$23.69M |
| Investing cash flow | -$118.86M | $0 |
| Financing cash flow | $159.14M | $60.48M |
| Stock-based compensation | $1.44M | $250.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Research and development | $18.61M | $20.93M | $14.33M | $11.45M |
| Selling, general and admin | $10.95M | $8.94M | $1.74M | $1.47M |
| Operating income | -$29.55M | -$29.86M | -$16.07M | -$12.91M |
| Pre-tax income | -$23.50M | -$27.23M | -$15.64M | -$12.40M |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$23.50M | -$27.23M | -$15.64M | -$12.40M |
| EPS, basic | -$0.58 | -$1.32 | -$24.19 | -$19.79 |
| EPS, diluted | -$0.58 | -$1.32 | -$24.19 | -$19.79 |
| Diluted shares | 40.4M | 22.7M | 744,641 | 736,933 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and equivalents | $319.33M | $168.41M | $8.60M | $32.44M |
| Current assets | $824.75M | $397.07M | - | - |
| Total assets | $825.74M | $397.36M | - | - |
| Current liabilities | $11.69M | $6.72M | - | - |
| Total liabilities | $12.12M | $6.72M | - | - |
| Shareholders' equity | $813.61M | $390.64M | -$76.07M | -$60.67M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Operating cash flow | -$14.49M | -$21.17M | -$15.64M | -$13.32M |
| Capital expenditures | $21.0K | $0 | $0 | $19.0K |
| Free cash flow | -$14.51M | -$21.17M | -$15.64M | -$13.34M |
| Investing cash flow | -$277.29M | -$101.30M | -$8.33M | -$15.75M |
| Financing cash flow | $442.70M | $269.11M | $129.0K | $8.42M |
| Stock-based compensation | $3.52M | $5.26M | $115.0K | $213.0K |
Key ratios
Source: XBRL data Veradermics Incorporated files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MANE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MANE | - | - | -$70.00M | - | $6.01B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MANE FAQ
6 questionsIs MANE profitable?
No. Veradermics Incorporated reported a net loss of $70.00M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does MANE have?
Veradermics Incorporated reported $319.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MANE free cash flow?
Veradermics Incorporated generated -$71.63M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$71.60M less capital expenditures.What is MANE earnings per share?
Diluted earnings per share were -$111.91 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did MANE last report financial results?
The latest statements here come from Veradermics Incorporated's 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this MANE financial data come from?
Quantisnow builds these statements from the structured XBRL data Veradermics Incorporated files with the SEC. It is provided for information only and is not investment advice.